Drug Trial Radar · NCT03235245
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
Last checked: Nov 20, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
271
Actual
Start
Oct 30, 2018
Primary completion
Oct 24, 2023
Study completion Jan 2027
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- First posted
- Aug 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective of this trial is to prospectively evaluate whether a sequential approach with an induction period of 12 weeks with encorafenib + binimetinib followed by combination immunotherapy with nivolumab + ipilimumab improves progression free survival compared to combination immunotherapy nivolumab + ipilimumab alone in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Conditions
- Unresectable Stage III Melanoma
- Stage IV Melanoma
Interventions
Nivolumab + IpilimumabDrug
nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
Encorafenib + BinimetinibDrug
encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: 4.1 years from first patient in
Locations
38 sites in 9 countries. Site status is shown where the registry gives one.
University Hospitals Copenhagen - Herlev Hospital - University Copenhagen
Herlev, Denmark
Odense University Hospital
Odense, Denmark
Helsinki University Central Hospital - Dept of Oncology
Helsinki, Finland
Tampere University Hospital
Tampere, Finland
CHU Amiens - Hopital Sud
Amiens, France
CHRU de Besançon - Hopital Jean Minjoz
Besançon, France
CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre
Bordeaux, France
Centre Jean Perrin
Clermont-Ferrand, France
CHU de Dijon - Centre Georges-François-Leclerc
Dijon, France
CHU de Grenoble - La Tronche - Hôpital A. Michallon
Grenoble, France
CHRU de Lille
Lille, France
Centre Hospitalier Lyon Sud
Lyon, France
Centre Leon Berard
Lyon, France
Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone (APHM)
Marseille, France
CHU de Nice - Hopital De L'Archet
Nice, France
Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis
Paris, France
CHU Ambroise Pare
Paris, France
Centre Hospitalier De Pau
Pau, France
CHU de Saint-Etienne - Hopital Nord
Saint-Priest-en-Jarez, France
CHU de Tours - Hopital Trousseau
Tours, France
Gustave Roussy
Villejuif, France
Universitaetsklinikum Heidelberg
Heidelberg, Germany
Univ. Mainz - Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz-University Medical Center
Mainz, Germany
Universitaetsklinikum Wuerzburg
Würzburg, Germany
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, Italy
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples, Italy
IRCCS - Istituto Oncologico Veneto
Padova, Italy
IRCCS-Regina Elena National Cancer Center
Roma, Italy
Universita Degli Studi Di Siena -Policlinico "le Scotte"
Siena, Italy
Azienda Ospedaliera Citta della Salute e della Scienza di Torino
Turin, Italy
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Udine, Italy
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
Amsterdam, Netherlands
Maria Sklodowska-Curie Memorial Cancer Centre
Warsaw, Poland
Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia)
Badalona, Spain
Hospital Clinic Universitari de Barcelona
Barcelona, Spain
Vall d'Hebron Institut d'Oncologia
Barcelona, Spain
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital
Glasgow, United Kingdom
East & North Hertfordshire NHS Trust - East and North Hertfordshire NHS Trust - Mount Vernon Hospital
Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.